Bayer Considers Divesting Dermatology Biz

Sep 08, 2016


Bayer AG is considering selling its dermatology business to push forward its deal with Monsanto Co., Bloomberg reported, citing sources. Bayer is working with JPMorgan Chase & Co. on the sale, which could be worth more than $1.12 billion.

The article noted the dermatology business could attract interest from existing makers of skincare products including Nestle SA's Galderma, Allergan Plc and Almirall SA, as well as private equity firms.

Read the Reuters story